News

A Phase 1/2 clinical trial evaluating ITI-214 in patients with Parkinson’s disease (PD) has begun enrolling patients, Intra-Cellular Therapies announced. ITI-214 is a potent and selective inhibitor of the phosphodiesterase 1 (PDE1) enzyme, which is involved in the degradation of both cAMP and cGMP (cyclic nucleotides). These are within-cell messengers for…

Researchers at Roche’s innovation center in Basel, Switzerland, have identified four small molecule therapy candidates that target the neurotensin receptor, a protein believed to play a role in the development of Parkinson’s and other neurological disorders. They used a double screening technique to narrow their list from thousands of possibilities…

Carbidopa, a medicine approved for the treatment of Parkinson’s disease, also has shown anti-cancer effects in lab-grown human cells and mice, according to the results of a new study. The findings help explain why cancer incidence usually is lower in Parkinson’s patients — with the exception of skin cancer — and…

Acadia Pharmaceuticals is starting a new Phase 3 clinical trial testing the efficacy of pimavanserin to treat the hallucinations and delusions associated with dementia-related psychosis in a broad array of patients with Parkinson’s, Alzheimer’s, and many other dementias. Pimavanserin, under the brand name Nuplazid, was approved by the U.S. Food and…

AC Immune is receiving additional funding from the Michael J. Fox Foundation for Parkinson’s Research to continue developing positron emission tomography (PET) tracers for alpha-synuclein, a protein linked to Parkinson’s disease. The idea behind the project is to use alpha-synuclein as a biomarker of Parkinson’s. The PET tracers will help…

Weight loss is common in Parkinson’s disease and can affect quality of life. A study has identified factors that can predict weight loss in patients who are in the early stages of Parkinson’s. They include being a woman, being older, having posture problems, having low cognitive scores, and using levodopa as a dopamine…

Herantis Pharma has started the first clinical trial of cerebral dopamine neurotrophic factor (CDNF) as a potential treatment for Parkinson’s disease. The first patient in the Phase 1/2 clinical trial has enrolled at the Karolinska University Hospital in Stockholm. The study will also involve another hospital in Sweden…

People with diabetes who use a group of drugs called glitazones are 28 percent less likely to develop Parkinson’s disease, report researchers from the University of Bergen (UiB) in Norway. But the study, published in the journal Movement Disorders, did not offer any insights into why that might be,…

Researchers at the Washington University School of Medicine (WUSM) in St. Louis developed a new computational method that can help predict if a patient will be diagnosed with Parkinson’s disease based solely on medical records. This new predictive algorithm was revealed in the report “A predictive model to identify Parkinson…

The abnormal alpha-synuclein characteristic of Parkinson’s disease interacts with the prion protein PrP, initiating a series of events that culminate in neuronal degeneration and cognitive impairment, a European study found. But a drug from the caffeine family prevented this interaction, reversing degeneration and Parkinson’s symptoms in mice. The study, “…